Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from AstraZeneca, Daiichi Sankyo, and Merck & Co.

Community Practice Connections™: Virtual Coffee Talk: Real World Applications of PARP, PI3K, and HER23 in Breast Cancer Care

Release Date: April 29, 2021
Expiration Date: April 29, 2022

Activity Overview

The past few years have realized approvals of several new targeted drugs for breast cancer based on increased understanding of the diverse genetic etiologies underlying this disease. The use of poly (ADP-ribose) polymerase (PARP) inhibitors has greatly expanded in the treatment of patients with BRCA1/2-mutated hormone receptor–positive or triple-negative breast cancer. Patients with PIK3CA-mutated hormone receptor–positive, HER2-negative advanced breast cancer, which has been associated with poor prognosis and treatment resistance, can now be treated with phosphoinositide 3-kinase (PI3K) inhibitors. Development of anticancer therapies that target the HER2 pathway has resulted in several new approvals for breast cancer in less than a year. With the complexity of current genetic test information, it is critical to examine recent clinical developments of these oncogenic targeted therapies and appreciate the implications for breast cancer treatment.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the live webcast satellite held in conjunction with the 38th Annual Miami Breast Cancer Conference®, held in March 2021. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with breast cancer, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AstraZeneca, Daiichi Sankyo, and Merck & Co.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational activity is directed toward medical oncologists who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of breast cancer are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Review the mechanistic rationale concerning the role of targeted therapies, including PARP inhibition, PI3K inhibition, and HER2/3 inhibition in breast cancer
  • Discuss strategies to integrate novel targeted approaches for the management of patients with breast cancer
  • Safely apply treatment approaches with oral targeted therapies in patients with breast cancer by managing treatment-associated toxicities
  • Evaluate emerging data and investigational targeted therapies among patients with breast cancer based on ongoing clinical trials

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible entities.

Chair

Kevin Kalinsky, MD, MS
Kevin Kalinsky, MD, MS
Acting Associate Professor
Department of Hematology and Medical Oncology
Emory University School of Medicine
Director, Breast Medical Oncology
Director, Glenn Family Breast Center
Winship Cancer Institute of Emory University
Atlanta, GA

Disclosures: Grant/Research Support: Acetylon Pharmaceuticals, Amgen, Calithera Biosciences, CytomX Therapeutics, Eli Lilly and Co, Genentech, Incyte Corporation, Pfizer, Seagen, Zeno Pharmaceuticals; Consultant: AstraZeneca, Biotheranostics, Eisai, Eli Lilly and Co, G1 Therapeutics, Novartis Pharmaceuticals, Pfizer.

Faculty

Aditya Bardia, MD, MPH
Aditya Bardia, MD, MPH
Director, Precision Medicine Center for Breast Cancer
Assistant Professor of Medicine Harvard Medical School
Attending Physician, Medical Oncology Massachusetts General Hospital
Boston, MA

Disclosures: Grant/Research Support: Daiichi Sankyo/AstraZeneca, Genentech, Immunomedics, Merck and Co, Novartis Pharmaceuticals, Pfizer, Radius Health, Sanofi; Consultant: Biotheranostics, Daiichi Sankyo/AstraZeneca, Eli Lilly and Co, Foundation Medicine Genentech, Immunomedics, Merck and Co, Novartis Pharmaceuticals, Pfizer, Philips, Puma Biotechnology, Radius Health, Sanofi, Taiho Oncology.

Komal Jhaveri, MD, FACP
Komal Jhaveri, MD, FACP
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant/Research Support: AstraZeneca, Debiopharm, Eli Lilly and Co, Genentech, Novartis Pharmaceuticals, Novita Pharmaceuticals, Pfizer, Puma Biotechnology, Zymeworks; Consultant: AbbVie, AstraZeneca, Blueprint Medicines, Eli Lilly and Co, Genentech, Jounce Therapeutics, Novartis Pharmaceuticals, Pfizer, Seagen, Taiho Oncology.

Jennifer K. Litton, MD
Jennifer K. Litton, MD
Chief, Section of Clinical Research and Drug Development
Department of Breast Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: AstraZeneca, EMD Serono, Genentech, Pfizer, Zenith Pharmaceuticals; Speakers’ Bureau: MedPage; Other: UpToDate (royalties).

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
      1
2345678
9101112131415
16171819202122
23242526272829
3031
Filter By